Qiagen & Protedyne target ultra-high volume diagnostics
This article was originally published in Clinica
Executive Summary
Qiagen, a leading supplier of nucleic acid and protein separation, purification and handling technology, has teamed up with Protedyne, a developer of high-throughput industrial robotic platforms, to target the market for ultra-high throughput systems - processing more than 600 samples per day - for molecular diagnostics and pharmaceutical research. As part of the deal, Venlo, the Netherlands-based Qiagen will invest $2m in Protedyne, of Windsor, Connecticut, and receive exclusive access to Protedyne's automation technologies for filter-based nucleic acid sample preparation.
You may also be interested in...
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.